Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Combining Evidence and Cost Effectiveness for HS
Description
The presentation discusses the challenges and strategies regarding the treatment of Hidradenitis Suppurativa (HS), incorporating evidence-based medicine and cost-effectiveness. HS treatments often borrow from psoriasis and acne therapies. The speaker emphasizes the importance of maximizing value in treatments amidst the financial burden many patients face, as one in five Americans have medical debt, impacting their access to healthcare and work productivity. The discussion highlights that patients with HS often frequent emergency departments due to flare-ups, leading to increased healthcare costs and lost wages. Despite limited studies on cost-effectiveness specific to HS, there's a need to evaluate treatment plans holistically, considering both financial and quality-of-life factors. The speaker advocates for personalized treatment strategies that balance medical therapies, procedures, and patient needs to improve outcomes and control costs. Emphasis is placed on procedural options like punch de-roofing, and the need for effective communication about treatment impact and management. The speaker expresses optimism for new treatments on the horizon while acknowledging the current reliance on existing surgical options and encouraging efficient use of available resources to enhance patient care.
View moreConclusions
- Hidradenitis Suppurativa (HS) treatment options often borrow from psoriasis and acne therapies.
- HS patients experience severe medical debt despite having health insurance.
- There is a high incidence of emergency department visits among HS patients, leading to increased healthcare costs.
- The average number of inpatient days and overall medical costs have risen for HS patients compared to psoriasis and control groups.
- HS significantly impacts patients' ability to work, with many missing substantial workdays due to flares.
- Patients with HS tend to have lower income levels and may be passed over for promotions due to their condition.
- The choice of medical treatments for HS is limited and often lacks robust cost-effectiveness data, motivating more innovative approaches to care.
- Procedural treatments like punch de-roofing can offer better outcomes and cost-effectiveness compared to traditional methods.
- Ongoing patient management should involve not just medications but also optimal wound care and consideration of mental health resources.
- There is a positive trend towards more effective treatments and better management strategies for HS patients.
- Kluender R, et al. Medical Debt in the US, 2009-2020. JAMA. 2021 Jul 20;326(3):250-256.
- Khalsa A, et al. JAAD. 2015;73:609.
- Kirby JS, et al. JAMA Dermatol. 2014;150(9):937.
- Matusiak L, et al. JAAD. 2010;62(4):706.
- Frings VG, et al. PLoS One. 2021;16(8):e0255560.
- Tzellos T, et al. Br J Dermatol. 2019;181:147.
- Van Straalen KR, et al. JAAD. 2021;84(5):1405.
- Sayed C, et al. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
- Riis PT, et al. JAAD. 2016;75(6):1151.
- Ferris LK, et al. JAMA Dermatol. 2020 Oct 1;156(10):1136.
- Vossen ARJV, et al. J Am Acad Dermatol. 2019;80(1):80.
- Ring HC, et al. Br J Dermatol. 2022;187(5):813.
- Mehdizadeh, et al. J Cut Med Surg. 2018;22(3):312.
- Mohamedahmed AYY, et al. Langenbeck's Archives of Surgery. 2021;406:981.
- Alavi A, Kirsner RS. JAAD. 2015;73(5):S55-61.
- Moloney S, et al. Journal of wound care. 2022;31 (11):898.
- Willems D, et al. J Med Econ. 2020;23(12):1516.